Latest Fate Therapeutics News & Updates

See the latest news and media coverage for Fate Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Fate Therapeutics

Biotechnology company developing engineered cell therapies

fatetherapeutics.com

Headquarters: San Diego, United States
Founded year: 2007
Company type: Public company
Number of employees: 50–250
Industry: Pharmaceuticals

Last updated Today

Latest news about Fate Therapeutics

In short: Fate Therapeutics advanced its CAR T pipeline: dosed first FT819 lupus patient in Phase 2 and received FDA clearance for FT839.

Company announcements

October 2 Fate Therapeutics

Fate Therapeutics grants employee inducement equity awards

The company issued stock options and restricted stock units to new non-executive hires on October 1, 2026. These grants vest over four years under Nasdaq Listing Rule 5635(c)(4).

September 25 Fate Therapeutics

Fate Therapeutics receives $15M grant for study

The award from CIRM supports the FT819 Phase 2 clinical trial, known as RECLAIM-LN.

August 13 Fate Therapeutics

Fate Therapeutics reports second quarter 2026 financial results and pipeline updates

The company dosed its first patient in a phase 2 lupus nephritis trial, secured FDA clearance for its next-generation CAR-T candidate, and reported a cash runway extending into 2028.

1 October 2024 Fate Therapeutics

Fate Therapeutics advances FT522 for autoimmune disease treatment

The company recently received FDA authorization to proceed with a Phase 1 trial evaluating the safety and efficacy of this cell therapy in multiple B cell-mediated conditions.

Media coverage

September 25 RTTNews

Fate Therapeutics Receives $15M CIRM Grant To Advance FT819 In Lupus Nephritis

Fate Therapeutics received a $15 million CIRM CLIN2 grant to support RECLAIM-LN, a Phase 2 potentially registrational trial of FT819, an off-the-shelf CD19 CAR T-cell...

August 14 Markets Insider

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites Trial advances FT819...

August 13 Financial Times

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated as an outpatient with same-day discharge FDA...

August 10 Investing.com

Fate Therapeutics earnings beat by $0.02, revenue topped estimates By Investing.com

Investing.com - Fate Therapeutics (NASDAQ: FATE) reported second quarter EPS of $-0.250, $0.02 better than the analyst estimate of $-0.270.

Never miss news about Fate Therapeutics

Track Fate Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Fate Therapeutics competitors & trending companies

Browse news for competitors to Fate Therapeutics and other trending companies.